Miravo Healthcare™ Announces First Quarter 2021 Results

  • Q1 2021 Adjusted Total Revenue – $14.5 million
  • Q1 2021 Adjusted EBITDA – $4.4 million
  • Blexten Canadian Prescriptions Increased 22% Year-Over-Year
  • Cambia Canadian Prescriptions Increased 9% Year-Over-Year

Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET

Mississauga, Ontario, Canada – May 17, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2021. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2021, which are available on the Company’s website (www.miravohealthcare.com). All figures are in Canadian dollars, unless otherwise noted.

Read full release here.